- Home
- APPS vs VERV Comparison
APPS vs VERV Comparison
Compare APPS & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- VERV
- Stock Information
- Founded
- APPS 2007
- VERV 2018
- Country
- APPS United States
- VERV United States
- Employees
- APPS N/A
- VERV N/A
- Industry
- APPS Multi-Sector Companies
- VERV Medicinal Chemicals and Botanical Products
- Sector
- APPS Miscellaneous
- VERV Health Care
- Exchange
- APPS Nasdaq
- VERV Nasdaq
- Market Cap
- APPS 534.2M
- VERV 475.0M
- IPO Year
- APPS N/A
- VERV 2021
- Fundamental
- Price
- APPS $4.23
- VERV $7.28
- Analyst Decision
- APPS Hold
- VERV Strong Buy
- Analyst Count
- APPS 4
- VERV 4
- Target Price
- APPS $2.38
- VERV $25.75
- AVG Volume (30 Days)
- APPS 13.0M
- VERV 1.3M
- Earning Date
- APPS 02-05-2025
- VERV 02-28-2025
- Dividend Yield
- APPS N/A
- VERV N/A
- EPS Growth
- APPS N/A
- VERV N/A
- EPS
- APPS N/A
- VERV N/A
- Revenue
- APPS $483,577,000.00
- VERV $24,396,000.00
- Revenue This Year
- APPS N/A
- VERV $106.46
- Revenue Next Year
- APPS $6.49
- VERV N/A
- P/E Ratio
- APPS N/A
- VERV N/A
- Revenue Growth
- APPS N/A
- VERV 219.91
- 52 Week Low
- APPS $1.18
- VERV $4.31
- 52 Week High
- APPS $6.86
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- APPS 53.51
- VERV 47.08
- Support Level
- APPS $5.01
- VERV $7.44
- Resistance Level
- APPS $6.86
- VERV $9.31
- Average True Range (ATR)
- APPS 0.74
- VERV 0.67
- MACD
- APPS -0.04
- VERV -0.12
- Stochastic Oscillator
- APPS 40.77
- VERV 14.01
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.